Greenwich LifeSciences, Inc. (GLSI)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Snehal S. Patel
|
CEO, CFO & Director | 1.1M | -- | 1964 |
|
Mr. Eric Rothe
|
Founder & Independent Director | -- | -- | 1975 |
|
Dr. Jaye L. Thompson Ph.D.
|
Vice President Clinical & Regulatory Affairs | -- | -- | 1966 |
|
Dr. Christine T. Fischette Ph.D.
|
VP of Business Development | -- | -- | 1951 |
Greenwich LifeSciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Greenwich LifeSciences, Inc. Earnings Date
